Does price deregulation increase drug price in China? An interrupted time series analysis

被引：1
作者：
Xiong, Yao [1 ,2 ]
Xu, Judy [1 ,2 ]
Gao, Yuexia [3 ]
机构：
[1] Southwestern Univ Finance & Econ, Sch Publ Adm, 555 Liutai Rd, Chengdu, Sichuan, Peoples R China
[2] Southwestern Univ Finance & Econ, Ctr Hlth Policy & Governance, Chengdu, Sichuan, Peoples R China
[3] Nantong Univ, Sch Publ Hlth, Nantong, Jiangsu, Peoples R China
来源：
INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT | 2021年 / 36卷 / 05期
基金：
中国国家自然科学基金;
关键词：
ceiling price; drug price; interrupted time series; price index; MEDICARE PART D; CARE; IMPACT; COST; EXPENDITURES;
D O I：
10.1002/hpm.3244
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Background The Chinese government removed the price ceiling of most drugs in June 2015 to establish a market-driven pricing system. The purpose of this study is to examine the impact of the elimination of drug ceiling price (EDCP) policy on drug prices. Methods Using a national macro-level dataset, we employed an interrupted time series method to study the abrupt level and gradual trend changes of Chinese and Western medicine consumer price index (CPI) between June 2014 and June 2017. Results The policy exerted level change on Chinese medicine CPI, increasing 0.201% (95% CI 0.026% to 0.376%, p = 0.026). And the trend in Chinese medicine CPI was still decreased nonsignificantly after the EDCP policy. However, there was no significant price change in Western medicine. Conclusion The EDCP policy has different effects on the prices of Chinese and Western medicines. Therefore, we need to pay more attention to the drug pricing mechanism in the future.
引用
收藏
页码：1653 / 1665
页数：13
相关论文
共 35 条
  • [1] Policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002
    Andersson, Karolina
    Petzold, Max Gustav
    Sonesson, Christian
    Lonnroth, Knut
    Carlsten, Anders
    [J]. HEALTH POLICY, 2006, 79 (2-3) : 231 - 243
  • [2] Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon, Omer
    Shavit, Oren
    Magnezi, Racheli
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (07) : 859 - 867
  • [3] A methodological framework for model selection in interrupted time series studies
    Bernal, J. Lopez
    Soumerai, S.
    Gasparrini, A.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2018, 103 : 82 - 91
  • [4] Chen Yixi, 2016, J Mark Access Health Policy, V4, DOI 10.3402/jmahp.v4.30458
  • [5] The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes
    Choi, Yoon Jeong
    Jia, Haomiao
    Gross, Tal
    Weinger, Katie
    Stone, Patricia W.
    Smaldone, Arlene M.
    [J]. DIABETES CARE, 2017, 40 (04) : 502 - 508
  • [6] Commission NHaFP, 2014, OP FULL PROM COMPR R
  • [7] Commssion NDaR, 2016, OP PROM MED SERV PRI
  • [8] Commssion NDaR, 2015, OP PROM DRUG PRIC RE
  • [9] Medicaid Prescription Drug Utilization and Expenditures Following Part D
    Farley, Joel F.
    Dusetzina, Stacie B.
    [J]. JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2010, 21 (02) : 715 - 728
  • [10] Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis
    Grijalva, Carlos G.
    Nuorti, J. Pekka
    Arbogast, Patrick G.
    Martin, Stacey W.
    Edwards, Kathryn M.
    Griffin, Marie R.
    [J]. LANCET, 2007, 369 (9568) : 1179 - 1186
1234